The Ervaxx mission
To capitalize on our proprietary insight into Dark Antigens™ to deliver targeted, off-the-shelf cancer vaccines and other immunotherapies to treat and prevent cancer.
Ervaxx is exploring the hidden depths of genomic dark matter to discover and characterize novel antigens selectively expressed by cancer cells. We are pioneering approaches to target these Dark Antigens™ for the design and development of off-the-shelf, cancer-specific vaccines and other immunotherapies.
Ervaxx is leveraging expertise in bioinformatics, immunopeptidomics and immunology to develop a differentiated technology platform designed to explore and commercialize this new and expanding antigenic repertoire to combat cancer.Read more about us
We have established a core team of scientists, entrepreneurs and industry veterans to drive our research, development and clinical success.View everyone
- Ervaxx presents research identifying melanoma-specific Dark Antigens™ at SITC 2019. CSO Dr. Ray Jupp presented data on Ervaxx’s lead program at the 34th Society for Immunotherapy of Cancer (SITC) annual meeting in National Harbor, MD, USA on Saturday 9th November 2019.
- Ervaxx launches to pioneer the use of Dark Antigens™ for the development of off-the-shelf cancer vaccines and T-cell receptor- based immunotherapies Ervaxx coincides its launch with the presentation of new research to identify novel melanoma-specific Dark Antigens by application of its novel EDAPT™ platform at The Society for Immunotherapy of Cancer 34th Annual Meeting (SITC).